Post-earnings recap
Reported
Tue, Aug 12, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Arrowhead Pharmaceuticals is still facing challenges, particularly with its earnings per share. Despite the miss on EPS, the stock saw a slight increase of 1.17%, possibly due to investor optimism about the company's long-term strategies. The lack of revenue figures and guidance may leave some investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -1.38% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current performance but remains focused on future objectives. They did not provide specific guidance for upcoming quarters.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized their focus on long-term goals despite short-term setbacks.